Summary
Cancer is a heterogeneous disease, meaning every tumour may addict to distinct oncogenic mechanisms and therefore need personalised treatment. This complexity could arise from genomic alterations (e.g. mutations), microenvironment changes (e.g. immune cells) and their interactions. Nevertheless, current therapeutic development mainly focuses on one of these alterations, resulting poor response in many cases.
Dr Haonan Lu was previously trained in bioinformatics and cell biology at Imperial College London. He is particularly interested in developing imaging-based methods to describe cancer phenotypes, as well as discovering novel therapeutic targets through functional genomics approach.
Publications
Journals
Talbot T, Lu H, Aboagye EO, 2023, Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal., Cancer Gene Ther, Pages:1-9
Palma Chaundler CS, Lu H, Fu R, et al., 2023, Kinetics and efficacy of antibody drug conjugates in 3D tumour models
Chen M, Lu H, Copley SJ, et al., 2023, A novel radiogenomics biomarker for predicting treatment response and pneumotoxicity from programmed cell death protein or ligand-1 inhibition immunotherapy in NSCLC, Journal of Thoracic Oncology, ISSN:1556-0864, Pages:1-13
Yan D, Lu H, Kaur A, et al., 2023, Development and optimisation of cationic lipid nanoparticles for mRNA delivery
Inglese M, Patel N, Linton-Reid K, et al., 2022, A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease, Communications Medicine, Vol:2, ISSN:2730-664X